396 related articles for article (PubMed ID: 31470642)
1. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
Valent P; Sadovnik I; Eisenwort G; Bauer K; Herrmann H; Gleixner KV; Schulenburg A; Rabitsch W; Sperr WR; Wolf D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31470642
[TBL] [Abstract][Full Text] [Related]
2. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
[TBL] [Abstract][Full Text] [Related]
3. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
[TBL] [Abstract][Full Text] [Related]
4. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.
van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH
Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
[TBL] [Abstract][Full Text] [Related]
6. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.
Valent P
Curr Cancer Drug Targets; 2011 Jan; 11(1):56-71. PubMed ID: 21062243
[TBL] [Abstract][Full Text] [Related]
7. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
8. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
9. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D; Helgason GV; Copland M
Nat Rev Cancer; 2020 Mar; 20(3):158-173. PubMed ID: 31907378
[TBL] [Abstract][Full Text] [Related]
10. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Holden JT; Geller RB; Farhi DC; Holland HK; Stempora LL; Phillips CN; Bray RA
Blood; 1995 Jul; 86(1):60-5. PubMed ID: 7540889
[TBL] [Abstract][Full Text] [Related]
12. Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
Copland M; Jørgensen HG; Holyoake TL
Hematology; 2005 Oct; 10(5):349-59. PubMed ID: 16203604
[TBL] [Abstract][Full Text] [Related]
13. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ
Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
Choi DC; Tremblay D; Iancu-Rubin C; Mascarenhas J
Ann Hematol; 2017 Jun; 96(6):919-927. PubMed ID: 28062906
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
16. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
17. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.
Schürch C; Riether C; Amrein MA; Ochsenbein AF
J Exp Med; 2013 Mar; 210(3):605-21. PubMed ID: 23401488
[TBL] [Abstract][Full Text] [Related]
19. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
20. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
Carter BZ; Mak DH; Cortes J; Andreeff M
Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
